相关实验视频

Updated: Jan 18, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

在miR-192-EGR1/HOXB9循环调节质瘤细胞干细胞和恶性表型,通过促进它们的介质细胞过渡调节

Guo-Wei Li¹, Yan-Ping Jin², Min-Feng Sheng³

¹School of Rehabilitation Science, Nanjing Normal University of Special Education, Nanjing, Jiangsu, China.

Journal of cellular and molecular medicine

|September 12, 2025

概括

微RNA-192 (miR-192) 通过降低EGR1和HOXB9.9的调节来抑制质瘤细胞恶性病变. 过度表达miR-192减少了增殖,入侵和茎,抑制了瘤的生长.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因规则基因规则

背景情况:

质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
微RNA (miRNAs) 在癌症的发展和进展中起着至关重要的作用.
在质瘤恶性表型中miR-192的特定作用需要进一步阐明.

研究的目的:

研究miR-192对质瘤细胞恶性表型的调节作用.
确定 miR-192 在质瘤中的功能背后的分子机制.
探索miR-192作为质瘤治疗点的潜力.

主要方法:

使用定量PCR,西式涂抹和免疫光来检测调节因素.
使用lentiviral等离子体转染来构建质瘤细胞模型.
用CCK-8,殖民地形成,Transwell,scratch和CD133+ GSC测试来评估细胞增殖,入侵,迁移和干细胞.
建立了皮下异种移植小鼠模型,以评估瘤生长 in vivo.

主要成果:

在质瘤样本中,MiR-192表达显著减少.
MiR-192直接降低了EGR1和HOXB9的监管,形成了一个监管循环.
过度表达miR-192显著降低了质瘤细胞的扩散,入侵和迁移.
过度表达EGR1或HOXB9取消了miR-192.2的抑制作用.
在体内,米R-192抑制了瘤生长,减少了茎状,并抑制了恶性表型.

结论:

MiR-192通过准EGR1/HOXB9轴,作为质瘤中的瘤抑制剂.
通过EGR1-HOXB9循环,MiR-192可以减少质瘤干和恶性表型.
MiR-192具有作为抑制质瘤进展的治疗剂的潜力.

关键词:

总体证券理事会的总体证券理事会.这是一个循环循环的循环.恶性现象型的恶性现象型.介酶体转化过程中的介酶体转化.树干性树干性

更多相关视频

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery

Published on: August 23, 2016

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

相关概念视频

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Somatic to iPS Cell Reprogramming

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...